pembrolizumab,adagrasib
mirati,merck
['pembro', 'krystal-7', 'lung', 'lcsm,(-blcsm)', 'krystal-1', 'mrtx849', 'adagrasib', 'thoracic', 'nsclc', 'krystal7', ' sg ', 'ca,022,i', ' ade ', 'sclc', 'alexander', 'mirati', 'shanghai,cell,therapy,group']
adagrasib + pembrolizumab as first-line treatment for patients with nsclc harboring a krasg12c mut. excellent response rates with manegeable toxicity. very proud to participate in the krystal7 trial #esmoimmuno22 #lcsm 
Associate Head Oncology. Fundación Jiménez Díaz. IIS - FJD. Head of Thoracic Oncology & Clinical Trials. Professor  @UAM_Madrid previously @RoyalFreeNHS London